CH621544A5 - - Google Patents
Download PDFInfo
- Publication number
- CH621544A5 CH621544A5 CH922276A CH922276A CH621544A5 CH 621544 A5 CH621544 A5 CH 621544A5 CH 922276 A CH922276 A CH 922276A CH 922276 A CH922276 A CH 922276A CH 621544 A5 CH621544 A5 CH 621544A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- fluoropyrimidine
- mixture
- reaction
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- -1 derivatives of 5-fluoropyrimidin-4-one (4-oxo-5-fluoropyrimidine) Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- NBAHQCCWEKHGTD-UHFFFAOYSA-N 5-fluoro-1h-pyrimidin-6-one Chemical class OC1=NC=NC=C1F NBAHQCCWEKHGTD-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- ZBVXJWHEULFSCQ-UHFFFAOYSA-N 5-fluoro-2,4-dihexadecoxypyrimidine Chemical compound CCCCCCCCCCCCCCCCOC1=NC=C(F)C(OCCCCCCCCCCCCCCCC)=N1 ZBVXJWHEULFSCQ-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NHOWDZOIZKMVAI-UHFFFAOYSA-N (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol Chemical compound C=1N=CN=CC=1C(C=1C(=CC=CC=1)Cl)(O)C1=CC=C(Cl)C=C1 NHOWDZOIZKMVAI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- DYWSJASQYRSYDM-UHFFFAOYSA-N 2,4-dibutoxy-5-fluoropyrimidine Chemical compound CCCCOC1=NC=C(F)C(OCCCC)=N1 DYWSJASQYRSYDM-UHFFFAOYSA-N 0.000 description 1
- LTFHAQJWOBCJPP-UHFFFAOYSA-N 2-butoxy-5-fluoro-1h-pyrimidin-6-one Chemical compound CCCCOC1=NC=C(F)C(=O)N1 LTFHAQJWOBCJPP-UHFFFAOYSA-N 0.000 description 1
- NBVWNOMMYSTUJX-UHFFFAOYSA-N 2-butoxy-5-fluoropyrimidine Chemical compound C(CCC)OC1=NC=C(C=N1)F NBVWNOMMYSTUJX-UHFFFAOYSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DYNKTSVNPQQPDC-UHFFFAOYSA-N 5-fluoro-2,4-bis(phenylmethoxy)pyrimidine Chemical compound N1=C(OCC=2C=CC=CC=2)C(F)=CN=C1OCC1=CC=CC=C1 DYNKTSVNPQQPDC-UHFFFAOYSA-N 0.000 description 1
- HWSXVIILMQHXMU-UHFFFAOYSA-N 5-fluoro-2-hexadecoxy-1h-pyrimidin-6-one Chemical compound CCCCCCCCCCCCCCCCOC1=NC=C(F)C(=O)N1 HWSXVIILMQHXMU-UHFFFAOYSA-N 0.000 description 1
- MEKOOGPQBMLMDC-UHFFFAOYSA-N 5-fluoro-2-phenoxy-1h-pyrimidin-6-one Chemical compound N1C(=O)C(F)=CN=C1OC1=CC=CC=C1 MEKOOGPQBMLMDC-UHFFFAOYSA-N 0.000 description 1
- KSPDSMOWMQFPBL-UHFFFAOYSA-N 5-fluoropyrimidine Chemical compound FC1=CN=CN=C1 KSPDSMOWMQFPBL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000004707 phenolate Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15093775A JPS6011033B2 (ja) | 1975-12-16 | 1975-12-16 | ５‐フルオルピリミジン―４―オン誘導体の製造法 |
| JP50150936A JPS6011032B2 (ja) | 1975-12-16 | 1975-12-16 | ２―置換―５―フルオルピリミジン―４―オン誘導体の製造法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH621544A5 true CH621544A5 (sv) | 1981-02-13 |
Family
ID=26480366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH922276A CH621544A5 (sv) | 1975-12-16 | 1976-07-19 | |
| CH629080A CH625230A5 (sv) | 1975-12-16 | 1980-08-20 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH629080A CH625230A5 (sv) | 1975-12-16 | 1980-08-20 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4080455A (sv) |
| AU (1) | AU505440B2 (sv) |
| CA (1) | CA1063606A (sv) |
| CH (2) | CH621544A5 (sv) |
| DE (1) | DE2633359C3 (sv) |
| DK (1) | DK137957B (sv) |
| FI (1) | FI61885C (sv) |
| FR (1) | FR2335228A1 (sv) |
| GB (1) | GB1501537A (sv) |
| NL (1) | NL162643C (sv) |
| NO (1) | NO143903C (sv) |
| SE (1) | SE439159B (sv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR68935B (sv) * | 1976-03-31 | 1982-03-29 | Takeda Chemical Industries Ltd | |
| JPS5446791A (en) * | 1977-09-22 | 1979-04-12 | Takeda Chem Ind Ltd | Fluorouracil derivative |
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| CN102532039B (zh) * | 2010-09-29 | 2014-03-26 | 浙江工业大学 | 一种5-氟嘧啶-4(3h)-酮类化合物在制备抗肿瘤药物中的应用 |
| CN101955465B (zh) * | 2010-09-29 | 2012-07-04 | 浙江工业大学 | 一种5-氟嘧啶-4(3h)-酮类化合物及其制备方法和应用 |
| CN102659689B (zh) * | 2012-05-16 | 2014-12-17 | 浙江工业大学 | 4-取代-2-丁氧基-5-氟嘧啶类化合物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) * | 1957-08-06 | S-eluorourace | ||
| US3784693A (en) * | 1972-10-18 | 1974-01-08 | Sandoz Ag | 3-substituted phenyl-quinazoline-4(3h)-ones as sedative hypnotics |
| CH579057A5 (sv) * | 1973-09-07 | 1976-08-31 | Hoffmann La Roche |
-
1976
- 1976-06-30 US US05/701,216 patent/US4080455A/en not_active Expired - Lifetime
- 1976-07-01 AU AU15475/76A patent/AU505440B2/en not_active Expired
- 1976-07-01 GB GB27373/76A patent/GB1501537A/en not_active Expired
- 1976-07-19 CH CH922276A patent/CH621544A5/de not_active IP Right Cessation
- 1976-07-21 SE SE7608306A patent/SE439159B/sv not_active IP Right Cessation
- 1976-07-24 DE DE2633359A patent/DE2633359C3/de not_active Expired
- 1976-07-27 CA CA257,901A patent/CA1063606A/en not_active Expired
- 1976-07-28 FI FI762166A patent/FI61885C/fi not_active IP Right Cessation
- 1976-07-28 FR FR7623012A patent/FR2335228A1/fr active Granted
- 1976-07-30 NO NO762664A patent/NO143903C/no unknown
- 1976-07-30 DK DK346176AA patent/DK137957B/da not_active IP Right Cessation
- 1976-07-30 NL NL7608537.A patent/NL162643C/xx not_active IP Right Cessation
-
1980
- 1980-08-20 CH CH629080A patent/CH625230A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU505440B2 (en) | 1979-11-22 |
| FR2335228A1 (fr) | 1977-07-15 |
| DE2633359C3 (de) | 1981-12-17 |
| FI61885C (fi) | 1982-10-11 |
| DE2633359B2 (de) | 1980-12-04 |
| SE7608306L (sv) | 1977-06-17 |
| US4080455A (en) | 1978-03-21 |
| FI61885B (fi) | 1982-06-30 |
| AU1547576A (en) | 1978-01-05 |
| NO762664L (sv) | 1977-06-17 |
| NL162643C (nl) | 1980-06-16 |
| DE2633359A1 (de) | 1977-06-30 |
| DK137957B (da) | 1978-06-12 |
| NL162643B (nl) | 1980-01-15 |
| NL7608537A (nl) | 1977-06-20 |
| NO143903B (no) | 1981-01-26 |
| GB1501537A (en) | 1978-02-15 |
| DK137957C (sv) | 1978-11-06 |
| DK346176A (sv) | 1977-06-17 |
| CA1063606A (en) | 1979-10-02 |
| FI762166A (sv) | 1977-06-17 |
| SE439159B (sv) | 1985-06-03 |
| NO143903C (no) | 1981-05-06 |
| FR2335228B1 (sv) | 1978-11-17 |
| CH625230A5 (sv) | 1981-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3100478A1 (de) | 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel | |
| DE3010040A1 (de) | Verfahren zur gewinnung von rosmarinsaeure aus melisse | |
| Bergmann et al. | Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine1 | |
| EP0354246A1 (de) | 3'-Azido-2',3'-dideoxynucleosid-5'-phosphonate | |
| CH621544A5 (sv) | ||
| DE2323746A1 (de) | Mono- und diester der 2,5-dihydroxybenzolsulfonsaeure | |
| CH467277A (de) | Verfahren zur Herstellung von Cobalticorrinoiden | |
| DE2928594A1 (de) | Neue verbindungen mit immunopotenzierender wirkung, arzneimittel, dieselben enthaltend, sowie verfahren zur herstellung derselben | |
| DE2065698C3 (de) | Verfahren zur Herstellung von 2-Isopropyl-6-methyl-4(3H)-pyrimidon | |
| AT356118B (de) | Verfahren zur herstellung neuer 5- -fluorpyrimidin-4-on-derivate | |
| DE3888694T2 (de) | Isoprenoid-derivate und arzneimittelzubereitung, die diese enthält. | |
| DE2412388A1 (de) | Dibenzothiophenderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
| DE68915750T2 (de) | Kathecholverbindungen, verfahren zur herstellung und arzneimittelzubereitung, die diese enthält. | |
| DE2455026A1 (de) | Therapeutisches mittel | |
| EP0095569A2 (de) | Verfahren zur Herstellung von Phenylpyridazinverbindungen | |
| DE1545581A1 (de) | Neue Penicillinaldehyde und Verfahren zu deren Herstellung | |
| DE1593832C3 (de) | Verfahren zur Herstellung von Calcium DL Pantothenat | |
| DE2003840A1 (de) | 3-Phenyl-4-acyloxycarbostyrile,Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
| AT365164B (de) | Verfahren zur herstellung des neuen pivaloyloxymethyl-2-propylpentanoats | |
| DE2443401A1 (de) | Neue aliphatisch substituierte arylchalkogeno-kohlenwasserstoffderivate und verfahren zu ihrer herstellung | |
| DE2043174C3 (de) | Zimtsäurederivate | |
| DE1768466A1 (de) | Neue ss-Phenylalanin-Derivate | |
| EP0478721B1 (de) | Neue benzocycloalkencarbonsäure und verfahren zu ihrer herstellung | |
| DE3306505C2 (de) | 4-Desmethoxy-13-dihydro-daunorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE1768142C (de) | Verfahren zur Herstellung von Herzglykosidderivaten und Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |